Updated Framework Redefines How Cancer Complexity Is Understood

A long-standing challenge in cancer research is just how complex it is. For instance, there are many different ways for cancers to originate, progress, and spread. In a review published recently in Cell, biologist Douglas Hanahan of the Ludwig Institute for Cancer Research, presents an updated version of his long-standing conceptual model designed to help scientists interpret the complex biology of cancer.

The framework, known as the Hallmarks of Cancer, was first outlined 26 years ago by Hanahan and Robert A. Weinberg of the Ludwig Center at MIT. It identified six key alterations in cell physiology believed to be shared across most cancers, helping malignant cells evade normal growth controls. The original publication and its 2011 update—which expanded the number of hallmarks to eight—have become foundational in cancer biology, together cited more than 75,000 times in scientific literature.

While the Hallmarks of Cancer has shaped decades of research, successive revisions and new discoveries have made the model increasingly intricate. “Its attractive simplicity has arguably become more complicated,” Hanahan writes. In this new review, he introduces a broader framework that situates the hallmarks within four interconnected dimensions describing how cancers arise and evolve.

The first dimension remains the set of hallmark traits—acquired cellular capabilities such as independence from anti-growth signals and the ability to stimulate new blood vessel formation—that all tumors share. The second comprises enabling characteristics, including genome instability, epigenetic reprogramming, and tumor-promoting inflammation, which allow cells to acquire hallmark features.

A third dimension highlights the role of normal cells, such as fibroblasts and immune cells, that become “accessories to the crime” when co‑opted by tumors to support cancer progression. The fourth adds systemic influences—such as aging and obesity—that Hanahan describes as “clouds of complexity” because they interact with cancer at every stage and shape both treatment strategies and patient well-being.

The review examines each of these dimensions in depth, covering nine cancer hallmarks, five enabling traits, seven classes of supporting cells, and two systemic factors. Hanahan also proposes that therapies targeting several hallmark capabilities simultaneously may achieve more lasting benefits than those focused on individual pathways.

Reflecting on the framework’s continuing relevance, Hanahan writes, “The conceptual premise set forward in January of the year 2000 has endured, remarkably and unexpectedly, for twenty-six years,” and he hopes the updated perspective “restores some of that conceptual clarity.”